Ryvu Therapeutics SA
WSE:RVU
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
39.7
64.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Ryvu Therapeutics SA
Accrued Liabilities
Ryvu Therapeutics SA
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
Accrued Liabilities
zł11.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
46%
|
CAGR 10-Years
13%
|
|
|
I
|
Inno-Gene SA
WSE:IGN
|
Accrued Liabilities
zł85k
|
CAGR 3-Years
-65%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Medicofarma Biotech SA
WSE:MDB
|
Accrued Liabilities
zł1.3m
|
CAGR 3-Years
215%
|
CAGR 5-Years
73%
|
CAGR 10-Years
N/A
|
|
|
S
|
Selvita SA
WSE:SLV
|
Accrued Liabilities
zł8.1m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Ryvu Therapeutics SA
Glance View
Ryvu Therapeutics SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 186 full-time employees. The company went IPO on 2011-07-14. The firm is active in the pharmaceutical and biotechnology fields. The company operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. The company operates through unit Ardigen SA and SORS Holdings Ltd.
See Also
What is Ryvu Therapeutics SA's Accrued Liabilities?
Accrued Liabilities
11.3m
PLN
Based on the financial report for Sep 30, 2024, Ryvu Therapeutics SA's Accrued Liabilities amounts to 11.3m PLN.
What is Ryvu Therapeutics SA's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
13%
Over the last year, the Accrued Liabilities growth was 7%. The average annual Accrued Liabilities growth rates for Ryvu Therapeutics SA have been 21% over the past three years , 46% over the past five years , and 13% over the past ten years .
You don't have any saved screeners yet
